2005 MAY 20 PM 12: 52

UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA

10 UNITED STATES OF AMERICA,

INFORMATION

12 ν.

13 DPC (TIANJIN) CO. LTD.,

Defendant.

[15 U.S.C. § 78dd-1: Foreign Corrupt Practices Act]

15 16

17

18

19

21

14

1

2

3

4

5

б

7

8

9

11

The United States Attorney charges:

[15 U.S.C. § 78dd-1]

At all times relevant to this Information:

20 la. INTRODUCTION

Diagnostic Products Corporation ("DPC") was a U.S. 22 corporation engaged in providing immunodiagnostic systems and 23 immunochemistry kits throughout the world and maintained its 24 principal place of business in Los Angeles, California. DPC was 25 an "issuer" within the meaning of the Foreign Corrupt Practices 26 Act, 15 U.S.C. § 78dd-1. As an issuer, DPC regularly filed its 27 financial statements with the U.S. Securities and Exchange 28 Commission. Defendant DPC (TIANJIN) CO. LTD., formerly Tianjin

1 Depu (DPC) Biotechnological and Medical Products, Inc. ["DPC 2 TIANJIN"] was a wholly-owned subsidiary of DPC that had its 3 principal place of business in Tianjin, China. Defendant DPC 4 TIANJIN acted as an agent of DPC within the meaning of the 5 Foreign Corrupt Practices Act, 15 U.S.C. § 78dd-1. Defendant DPC 6 ||TIANJIN's financial results were a component of the consolidated 7 financial statements included in DPC's filings with the U.S. Securities and Exchange Commission.

- 9 Defendant DPC TIANJIN's main business operations were 2. 10 to produce and sell DPC TIANJIN's immunodiagnostic systems, 11 immunochemistry kits, and other medical equipment. The main 12 source of revenue of defendant DPC TIANJIN was from sales of its 13 [immunoassays (test kits), which were utilized to identify and 14 measure medically significant chemical substances. The clinical 15 papplications of these immunoassays related to the diagnosis and 16 management of thyroid, reproductive, and cardiac disorders; 17 |infectious diseases; anemia; diabetes; and certain types of 18 cancer.
- 19 The Foreign Corrupt Practices Act of 1977 ("FCPA"), as amended, 15 U.S.C. §§ 78dd-1, et seg., prohibited payments to 21 foreign government officials to obtain or retain business.

23 PAYMENTS TO FOREIGN GOVERNMENT OFFICIALS

24 Commission Payments

At least as early as late 1991 and continuing through 26 on or about December 12, 2002, defendant DPC TIANJIN made cash

27

25

22

1 commission payments to laboratory personnel and doctors employed 2 by hospitals owned by the government of the People's Republic of 3 China (the "hospitals") to obtain and retain certain business 4 involving the sale of immunodiagnostic systems, immunochemistry 5 kits, and other medical equipment. The hospitals were 6 instrumentalities of the government of the People's Republic of 7 China, and the laboratory personnel and doctors were "foreign 8 officials" as that term is defined in the FCPA, 15 U.S.C. § 78dd-9 (1 (f) (1) (A).

- 5. Defendant DPC TIANJIN entered into sales agreements and 11 purchase orders with certain of these hospitals in the People's 12 Republic of China for immunodiagnostic systems, immunochemistry 13 kits, and other medical equipment. The practice of entering into 14 such agreements was authorized by the General Manager of 15 defendant DPC TIANJIN, on behalf of the defendant.
- 6. Although defendant DPC TIANJIN was a major provider in 17 the People's Republic of China of immunociagnostic systems, 18 | immunochemistry kits, and other medical equipment, there were 19 other manufacturers and suppliers in the People's Republic of 20 China with whom defendant DPC TIANJIN competed. In order to 21 obtain and retain business with these hospitals for the sales of 22 immunodiagnostic systems, immunochemistry kits, and other medical 23 equipment, defendant DPC TIANJIN, acting through its officers and 24 agents, entered into sales agreements with people employed by the 25 hospitals -- usually the laboratory heads or assistants --26 whereby these employees would receive commissions on defendant

10

1 DPC TIANJIN's sales of immunodiagnostic systems, immunochemistry 2 kits, and other medical equipment (hereinafter referred to as the 3 "commission payments"). The commission payments were generally 4 3-5%, but scmetimes as high as 20%, of the gross sales generated 5 by the contracts. The responsible officers of defendant DPC 6 TIANJIN understood that the hospitals would not have entered into 7 or maintained their business with the defendant if such 8 commission payments had not been made.

- The General Manager of defendant DPC TIANJIN authorized 10 hand deliveries of the commission payments, in cash, as well as Il by mail and wire transfers.
- 8. From in or about late 1991, through on or about 13 December 12, 2002, defendant DPC TIANJIN made commission payments 14 totaling approximately \$1,623,326 to laboratory department heads 15 and assistants in several hospitals in China, as follows:

16	<u>Date</u>	Amount	of	Commission Payments
17	1991			\$6,349
18	1992			\$33,159
19	1993	•		\$42,340
20	1994			\$37,724
21	1995			\$88,433
22	1996			\$97,058
23	1997			\$121,446
24	1998			\$140,934
25	1999			\$180,940
26	2000			\$262,487
27				

12

2001 \$301,305 2002 \$311,151

Authorization and Recording of the Payments

- Defendant DPC TIANJIN recorded the commission payments 9. on its books and records as "selling expenses." DPC regularly 6 |incorporated defendant DPC TIANJIN's selling expenses amount into 7 lits consolidated financial statements which then were included in filings to the U.S. Securities and Exchange Commission. 9 General Manager and Deputy General Manager of defendant DPC 10 TIANJIN regularly prepared and submitted to DPC reports 11 containing defendant DPC TIANJIN's financial statements. 12 Defendant DPC TIANJIN routinely sent these reports by electronic 13 mail message and facsimile to DPC's principal place of business 14 in Los Angeles, California.
- The General Manager of defendant DPC TIANJIN authorized 15 16 the practice of paying the commission payments to the employees 17 of the hospitals. The General Manager of defendant DPC TIANJIN 18 also approved and caused to be approved the budgets for sales 19 expenses of DPC TIANJIN, which included the commission payments 20 that DPC TIANJIN intended to pay to the employees of the 21 hospitals in the following quarter or year. Defendant DPC 22 |TIANJIN caused approval of the proposed budgets to be sent by telephone, facsimile, and electronic mail from Los Angeles, 23 24 California, to Tianjin, China.

25 ///

26

1

2

3

4

27

FOREIGN CORRUPT PRACTICES ACT VIOLATION

In or about November 2002, in the Central District of California and elsewhere, defendant, DPC TIANJIN used electronic 3 mail and other means and instrumentalities of interstate commerce corruptly in furtherance of an offer, promise to pay, and authorization of the payment of money to officials of the government of the People's Republic of China, for the purpose of 8 influencing the acts and decisions of said foreign officials in 9 their official capacities; inducing said foreign officials to do 10 and cmit to do acts in violation of their lawful duty; securing 11 an improper advantage; and inducing said foreign officials to use 12 their influence with instrumentalities of a foreign government to 13 affect and influence acts and decisions of said instrumentalities 14 of a foreign government in order to assist defendant DPC TIANJIN 15 in obtaining and retaining business for and with, and directing 16 business to, defendant, to wit, DPC TIANJIN made payments to foreign government officials, that is, doctors and laboratory 18 personnel employed by hospitals owned by the government of the People's Republic of China, in order to secure and maintain 20 agreements for the sale of immunodiagnostic systems, immunochemistry kits, and other medical equipment, and caused to 22 be sent an electronic mail message from Tianjin, China to Los ///

24

23

1

2

25

26

27

1	Angeles, California containing a monthly report concerning the
2	allowance of said payments.
3	
4	
5	DEBRA WONG YANG
6	United States Attorney
7	
8	STEVEN D. CLYMER Special Assistant United States
9	Attorney Chief, Criminal Division
10	JOSHUA R. HOCHBERG
11	Chief, Fraud Section Criminal Division
12	
13	MARK F. MENDELSOHN Deputy Chief, Fraud Section
14	Criminal Division
15	ADRIAN D. MEBANE
16	Trial Attorney Criminal Division
17	United States Department of Justice
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	· -7-